Scientists tame chaotic protein fueling 75% of cancers
MYC is the shapeless protein responsible for making the majority of human cancer cases worse. UC Riverside researchers have found a way to rein it in, offering hope for a new era of treatments.
MYC is the shapeless protein responsible for making the majority of human cancer cases worse. UC Riverside researchers have found a way to rein it in, offering hope for a new era of treatments.
Biochemistry
Jan 11, 2024
0
468
A new publication in the May issue of Nature Aging by researchers from Integrated Biosciences, a biotechnology company combining synthetic biology and machine learning to target aging, demonstrates the power of artificial ...
Biotechnology
May 8, 2023
0
6801
Quantum advantage is the milestone the field of quantum computing is fervently working toward, where a quantum computer can solve problems that are beyond the reach of the most powerful non-quantum, or classical, computers.
Quantum Physics
Nov 20, 2023
1
153
Researchers at the University of Alberta have uncovered what they say has been the missing puzzle piece ever since the genetic code was first cracked.
Cell & Microbiology
Feb 28, 2024
0
224
A new nanotechnology development by an international research team led by Tel Aviv University researchers will make it possible to generate electric currents and voltage within the human body through the activation of various ...
Nanophysics
Jul 6, 2021
0
561
Discovering and developing drugs can be slow, costly and high-risk, but harnessing advances in artificial intelligence (AI) can help with these processes, say Brock University researchers.
Molecular & Computational biology
Aug 1, 2023
0
30
Imagine the marriage of hard metals or semiconductors to soft organic or biological products. Picture the strange, wonderful offspring -- hybrid materials never conceived by Mother Nature.
Nanophysics
Apr 19, 2010
1
0
Eve, an artificially-intelligent 'robot scientist' could make drug discovery faster and much cheaper, say researchers writing in the Royal Society journal Interface. The team has demonstrated the success of the approach as ...
Hi Tech & Innovation
Feb 3, 2015
4
2698
Researchers from the University of Sussex and Universal Quantum have demonstrated for the first time that quantum bits (qubits) can directly transfer between quantum computer microchips and demonstrated this with record-breaking ...
Quantum Physics
Feb 8, 2023
0
640
The online cover story of Science Advances this week features a conceptual gastrointestinal (GI) microdevice, developed by a research team for extended drug release. Drug delivery platforms for extended drug release have ...
In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are discovered and/or designed.
In the past most drugs have been discovered either by identifying the active ingredient from traditional remedies or by serendipitous discovery. A new approach has been to understand how disease and infection are controlled at the molecular and physiological level and to target specific entities based on this knowledge.
The process of drug discovery involves the identification of candidates, synthesis, characterization, screening, and assays for therapeutic efficacy. Once a compound has shown its value in these tests, it will begin the process of drug development prior to clinical trials.
Despite advances in technology and understanding of biological systems, drug discovery is still a lengthy, "expensive, difficult, and inefficient process" with low rate of new therapeutic discovery. Information on the human genome, its sequence and what it encodes has been hailed as a potential windfall for drug discovery, promising to virtually eliminate the bottleneck in therapeutic targets that has been one limiting factor on the rate of therapeutic discovery.[citation needed] However, data indicates that "new targets" as opposed to "established targets" are more prone to drug discovery project failure in general[citation needed] This data corroborates some thinking underlying a pharmaceutical industry trend beginning at the turn of the twenty-first century and continuing today which finds more risk aversion in target selection among multi-national pharmaceutical companies.[citation needed]
This text uses material from Wikipedia, licensed under CC BY-SA